ArticleJournal of affective disorders2025
Comparison of effectiveness and side effects of selegiline transdermal system versus oral monoamine oxidase inhibitors and tricyclic antidepressants for treatment-resistant depression.
Article in Journal of affective disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Progress, critical challenges, and translational prospects of intranasal administration of botanical essential oils for the treatment of depression.Frontiers in pharmacology · 2025Pooled it
- Selective inhibition of monoamine oxidase B represents a therapeutic strategy for diabetic peripheral neuropathy.Acta pharmacologica Sinica · 2026Article
- Bromocriptine, Selegiline and Amantadine in the Treatment of Depression-A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionSeveral studies suggest that oral monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) may be more effective than serotonin reuptake inhibitors for treating treatment-resistant depression (TRD). Despite this advantage, they are now rarely prescribed due to concern over serious side effects. In contrast, selegiline transdermal system (STS) may present a safer alternative to oral MAOIs and TCAs; however, no studies have compared STS with other antidepressants.
methodsData from 117 patients who received STS, oral MAOIs, or TCAs for TRD were obtained from a university mood disorder clinic. Two linear regression models were created with severity and number of side effect categories endorsed as the dependent variable. Logistic regression models were created for each side effect category with presence of category as the dependent variable. In all models, antidepressant class was entered as the independent variable, with covariates.
resultsAlthough STS was less effective than oral MAOIs, it was significantly more effective than TCAs. STS treatment had significantly fewer side effect categories endorsed versus oral MAOIs and TCAs. Patients receiving STS were less likely to report gastrointestinal side effects versus TCAs and to endorse cardiovascular side effects versus oral MAOIs. In contrast, STS patients were more likely to report skin side effects versus oral MAOIs. There were no reported serious adverse events. Amongst the covariates, only the number of prior antidepressant trials predicted more side effect categories endorsed.
conclusionsAlthough oral MAOI therapy has been eschewed by most clinicians, STS may be better tolerated than oral MAOIs and TCAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.